Martin Wernli

3.5k total citations
47 papers, 2.2k citations indexed

About

Martin Wernli is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Martin Wernli has authored 47 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 10 papers in Pathology and Forensic Medicine. Recurrent topics in Martin Wernli's work include Chronic Lymphocytic Leukemia Research (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Lymphoma Diagnosis and Treatment (7 papers). Martin Wernli is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Lymphoma Diagnosis and Treatment (7 papers). Martin Wernli collaborates with scholars based in Switzerland, United States and Germany. Martin Wernli's co-authors include David Schwappach, Roger Stupp, Daniel Betticher, Hanspeter Honegger, Arnaud Roth, Rolf A. Stahel, Markus Borner, Thomas Cerny, Piercarlo Saletti and Mario Bargetzi and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

Martin Wernli

47 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Martin Wernli Switzerland	25	953	840	403	403	249	47	2.2k
Norbert Marschner Germany	25	649 0.7×	1.3k 1.5×	170 0.4×	185 0.5×	187 0.8×	153	2.2k
Massimo Magagnoli Italy	26	519 0.5×	1.1k 1.3×	565 1.4×	1.8k 4.6×	177 0.7×	83	2.7k
H. Anderson Sweden	28	603 0.6×	1.4k 1.7×	127 0.3×	579 1.4×	142 0.6×	51	2.8k
Jamey Skillings Canada	18	514 0.5×	1.3k 1.5×	128 0.3×	311 0.8×	180 0.7×	40	2.1k
Wayne Rackoff United States	19	945 1.0×	1.0k 1.2×	275 0.7×	117 0.3×	823 3.3×	35	2.9k
Nam P. Nguyen United States	30	1.8k 1.9×	807 1.0×	187 0.5×	221 0.5×	337 1.4×	165	4.0k
Michael Goodyear Canada	21	546 0.6×	784 0.9×	123 0.3×	170 0.4×	204 0.8×	36	2.4k
J R Anderson United States	27	1.1k 1.2×	1.6k 1.9×	666 1.7×	1.5k 3.7×	700 2.8×	50	3.9k
Andrea Veronesi Italy	28	676 0.7×	1.6k 1.9×	172 0.4×	286 0.7×	47 0.2×	135	2.8k
Carlo Tondini Italy	28	476 0.5×	1.2k 1.4×	146 0.4×	551 1.4×	224 0.9×	104	2.3k

Countries citing papers authored by Martin Wernli

Since Specialization

Citations

This map shows the geographic impact of Martin Wernli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Wernli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Wernli more than expected).

Fields of papers citing papers by Martin Wernli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Wernli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Wernli. The network helps show where Martin Wernli may publish in the future.

Co-authorship network of co-authors of Martin Wernli

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Wernli. A scholar is included among the top collaborators of Martin Wernli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Wernli. Martin Wernli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schwappach, David, et al.. (2010). Oncology Nurses' Perceptions About Involving Patients in the Prevention of Chemotherapy Administration Errors. Oncology nursing forum. 37(2). E84–E91. 48 indexed citations

Schwappach, David & Martin Wernli. (2010). Barriers and facilitators to chemotherapy patients’ engagement in medical error prevention. Annals of Oncology. 22(2). 424–430. 27 indexed citations

Schwappach, David & Martin Wernli. (2010). Am I (un)safe here? Chemotherapy patients' perspectives towards engaging in their safety. BMJ Quality & Safety. 19(5). e9–e9. 48 indexed citations

Schwappach, David & Martin Wernli. (2009). Medication errors in chemotherapy: incidence, types and involvement of patients in prevention. A review of the literature. European Journal of Cancer Care. 19(3). 285–292. 98 indexed citations

Bargetzi, Mario, et al.. (2009). DV‐ICE, intensive induction and early transplantation for adult patients with acute lymphoblastic leukemia: a phase II study. European Journal Of Haematology. 83(6). 512–518. 2 indexed citations

Moosmann, Peter, et al.. (2008). Weekly Treatment with a Combination of Bendamustine and Bortezomib in Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma: A Single- Center Phase 1/2 Study.. Blood. 112(11). 1574–1574. 6 indexed citations

Roth, Arnaud, Nicola Fazio, Roger Stupp, et al.. (2007). Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer Research. Journal of Clinical Oncology. 25(22). 3217–3223. 195 indexed citations

Leyvraz, Serge, Richard Herrmann, L Guillou, et al.. (2006). Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies. British Journal of Cancer. 95(10). 1342–1347. 8 indexed citations

Ghielmini, Michele, Kaspar Rufibach, Gilles Salles, et al.. (2005). Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Annals of Oncology. 16(10). 1675–1682. 121 indexed citations

10.

Kwiatkowski, Maciej, Andreas Huber, Bernhard Stamm, et al.. (2003). Features and preliminary results of prostate cancer screening in Canton Aargau, Switzerland. British Journal of Urology. 92(s2). 44–47. 16 indexed citations

11.

Betticher, Daniel, Shu-Fang Hsu Schmitz, Martin Tötsch, et al.. (2003). Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pN2 Non–Small-Cell Lung Cancer: A Multicenter Phase II Trial. Journal of Clinical Oncology. 21(9). 1752–1759. 323 indexed citations

12.

Rohr, A. von, S.‐F. Hsu Schmitz, André Tichelli, et al.. (2002). Treatment of hairy cell leukemia with cladribine(2-chlorodeoxyadenosine) by subcutaneous bolus injection:a phase II study. Annals of Oncology. 13(10). 1641–1649. 37 indexed citations

13.

Morant, R., S.‐F. Hsu Schmitz, J. Bernhard, et al.. (2002). Vinorelbine in androgen-independent metastatic prostatic carcinoma—a phase II study. European Journal of Cancer. 38(12). 1626–1632. 25 indexed citations

14.

Heizmann, Marc, Peter Itin, Martin Wernli, Luca Borradori, & Mario Bargetzi. (2001). Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: Report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. American Journal of Hematology. 66(2). 142–144. 106 indexed citations

15.

Bargetzi, Mario, Dominique Mühlematter, André Tichelli, Martine Jotterand, & Martin Wernli. (1999). Dicentric Translocation (9;12) Presenting as Refractory Philadelphia Chromosome-Positive Acute B-Cell Lymphoblastic Leukemia. Cancer Genetics and Cytogenetics. 113(1). 90–92. 6 indexed citations

16.

Betticher, Daniel, Daniel Ratschiller, S.‐F. Hsu Schmitz, et al.. (1998). Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Annals of Oncology. 9(7). 721–726. 24 indexed citations

17.

Kwiatkowski, Maciej, Franz Recker, Timo Piironen, et al.. (1998). In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic “gray zone” of total PSA 4 to 10 ng/mL. Urology. 52(3). 360–365. 103 indexed citations

18.

Recker, Franz, Maciej Kwiatkowski, Timo Piironen, et al.. (1998). The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma. Cancer. 83(12). 2540–2547. 39 indexed citations

19.

Egger, Thomas, Aloïs Gratwohl, Jakob Passweg, et al.. (1995). Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients. Supportive Care in Cancer. 3(2). 139–146. 35 indexed citations

20.

Tichelli, André, Aloïs Gratwohl, Peter Schumacher, et al.. (1990). Evaluation of the Sysmex R-1000®: An Automated Reticulocyte Analyzer. American Journal of Clinical Pathology. 93(1). 70–78. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact